Results 11 to 20 of about 80,266 (330)

Salt Stress Alleviation in Triticum aestivum Through Primary and Secondary Metabolites Modulation by Aspergillus terreus BTK-1

Frontiers in Plant Science, 2022
We report the growth promoting potential in wheat under saline conditions by an endophytic fungus Aspergillus terreus BTK-1. The isolated BTK-1 from the root of Chenopodium album was identified as Aspergillus terreus through 18S rDNA sequence analysis ...
Muhammad Ikram Khan, Niaz Ali, Gul Jan, Muhammad Hamayun, Farzana Gul Jan, Amjad Iqbal, Anwar Hussain, In-Jung Lee   +7 more
doaj   +2 more sources

Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib

PLoS ONE, 2023
Bruton’s tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-
David Y. Lin, Amy H. Andreotti
doaj   +2 more sources

Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models [PDF]

Blood Advances, 2022
Key Points • Although the potency of BTK degradation by UBX-382 is remarkable, cereblon neosubstrates are degraded in a cell type–dependent manner.• UBX-382 can dramatically degrade resistance-associated mutations such as E41K, C481S/R/T/Y/F, and L528W ...
Ye Seul Lim, Sun Mi Yoo, Vineet Patil, Han Wool Kim, Hyun-Hwi Kim, Beomseon Suh, Ji Youn Park, Na-rae Jeong, Chi Hoon Park, Je Ho Ryu, Byung‐Hoon Lee, Pilho Kim, Song Hee Lee   +12 more
openalex   +2 more sources

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.

New England Journal of Medicine, 2023
BACKGROUND Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed.
A. Mato, J. Woyach, Jennifer R. Brown, P. Ghia, K. Patel, T. Eyre, T. Munir, E. Lech-Maranda, N. Lamanna, C. Tam, Nirav N Shah, Catherine C Coombs, C. Ujjani, B. Fakhri, C. Cheah, M. Patel, A. Alencar, Jonathon B. Cohen, J. Gerson, I. Flinn, Shuo Ma, D. Jagadeesh, J. Rhodes, F. Hernandez-Ilizaliturri, P. Zinzani, J. Seymour, M. Balbas, B. Nair, P. Abada, Chunxiao Wang, A. Ruppert, Denise Y Wang, D. Tsai, W. Wierda, W. Jurczak   +34 more
semanticscholar   +1 more source

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor

Blood, 2023
Key Points • Pirtobrutinib is a potent, noncovalent (reversible), highly selective inhibitor of BTK and C481-mutant BTK.• Pirtobrutinib is efficacious in B-cell models in vitro and in vivo, including patient-derived CLL cells.
E. Gómez, K. Ebata, Hetal S Randeria, M. Rosendahl, E. P. Cedervall, T. Morales, Lauren M. Hanson, Nicholas E. Brown, Xueqian Gong, J. Stephens, Wenjuan Wu, Isabel Lippincott, Karin S Ku, R. Walgren, P. Abada, J. Ballard, C. Allerston, B. Brandhuber   +17 more
semanticscholar   +1 more source

Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects

Frontiers in Cell and Developmental Biology, 2021
The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and survival of B-lineage cells and, hence, represents a suitable drug target.
H. Y. Estupiñán, A. Berglöf, R. Zain, C. I. Smith   +3 more
semanticscholar   +1 more source

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

Blood Advances, 2023
Key Points • One-third of patients with CLL relapsing on ibrutinib do not carry BTK/PLCG2 mutations, even with a 0.1% sensitivity.• Additional mechanisms, such as del(8p), EGR2 and NF-κB pathway mutations, may be cooperating in determining progression on
S. Bonfiglio, L. Sutton, V. Ljungström, A. Capasso, Tatjana Pandzic, Simone Weström, H. Foroughi-Asl, A. Skaftason, A. Gellerbring, Anna Lyander, F. Gandini, G. Gaidano, L. Trentin, L. Bonello, G. Reda, Csaba Bödör, N. Stavroyianni, C. Tam, R. Marasca, F. Forconi, P. Panayiotidis, I. Ringshausen, O. Jakšić, A. Frustaci, S. Iyengar, M. Coscia, S. Mulligan, L. Ysebaert, V. Strugov, C. Pavlovsky, R. Walewska, A. Österborg, D. Cortese, P. Ranghetti, P. Baliakas, K. Stamatopoulos, L. Scarfò, R. Rosenquist, P. Ghia   +38 more
semanticscholar   +1 more source

Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors

Exploration of Targeted Anti-tumor Therapy, 2020
Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell receptor signaling and the irreversible BTK inhibitor ...
Rachael Arthur, Beatriz Valle-Argos, Andrew J. Steele, Graham Packham   +3 more
doaj   +1 more source

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

Blood, 2023
Introduction: BTK inhibitors (BTKis) are approved for chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL).
J. Seymour, C. Cheah, Ricardo D. Parrondo, Meghan C. Thompson, Don A. Stevens, M. Lasica, Michael L. Wang, Abhijeet Kumar, J. Trotman, M. Alwan, W. Ding, Kunthel By, Bilal Tariq, Xiangmei Chen, S. Fabre, J. Paik, Amit Agarwal, Constantine S. Tam   +17 more
semanticscholar   +1 more source

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

Journal of Hematology & Oncology, 2022
Bruton’s tyrosine kinase (BTK) is an essential component of multiple signaling pathways that regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising therapeutic target for various B cell malignancies and ...
Aqu Alu, H. Lei, Xuejiao Han, Yuquan Wei, Xiawei Wei   +4 more
semanticscholar   +1 more source